Purpose: Patellar tendinosis (PT) is a common condition amongst athletes. In this study, we perform a metaanalysis on randomised controlled trials (RCTs) to evaluate the use of plateletrich plasma (PRP) for refractory PT. Methods: A literature search was undertaken in various databases from their year of inception to October 2015. The primary outcome measure was the Victorian Institute of Sports AssessmentPatella (VISAP) score. Results: We identified 2 RCTs comparing PRP injections to alternative treatment options (extracorporeal shockwave therapy [ESWT] and dry needling of the tendon). Metaanalysis showed no significant difference in mean VISAP scores between PRP injection and control at early assessment (2 or 3 months; estimated difference in means, 11.9; standard error [SE], 7.4; 95% confidence interval [CI], -2.7 to 26.4; p=0.109). However, PRP was statistically better than control with regards to VISAP scores at longer followup (6 months or longer; estimated difference in means, 12.7; SE, 4.4; 95% CI, 4.1 to 21.3; p=0.004).
Introduction
Patellar tendinosis (PT) is a clinical syndrome characterised by anterior knee pain and tenderness at the insertion of the patel lar tendon on the inferior pole of the patella. Commonly known as "jumper's knee", PT causes pain following repetitive running or jumping exercises, which usually settles with rest but returns when exercise is recommenced 1) . A crosssectional study by Lian et al. 2) showed that 22% of the 613 interviewed athletes either cur rently had symptoms of PT (14%) or had previously experienced symptoms of PT (8%). The prevalence of PT varied significantly between sports: volleyball and basketball showed the highest prevalence with 45% and 32% of participants affected, respec tively; however, cycling had none, suggesting a relation to sports requiring high speed and power of the knee extensors. PT can have a prolonged disease course, refractory to first line nonsurgical treatments (such as patellar tendon eccentric exercises), which can lead to many patients requiring additional intervention 3) . Plateletrich plasma (PRP) injections have been shown to be beneficial to the healing and repair process of dis eased or injured tendons, and have been used with promising re sults in tendinopathies such as epicondylitis 4) and Achilles tendi nosis 5) . Uncontrolled clinical studies have reported that PRP can improve symptoms in PT 6, 7) ; however, before the wide use of PRP can be recommended, highquality controlled research evidence is required 8, 9) . Hence the aim of this study was to review the cur rent literature with regards to randomised controlled trials (RCTs) that have compared PRP injections with other treatment options for PT and carry out a metaanalysis, pooling the results of such trials.
Methods
A search of PubMed, EMBASE, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and Cochrane CENTRAL (Central Register of Controlled Trials) was conducted from their year of inception to October 2015 with the keywords: "patella" and "platelet", followed by a search with the keywords: "patel lar" and "platelet". Broad search keywords were used, rather than specific terms, to ensure no articles were missed. There was no language limit and only fully published articles or abstracts were included. The Preferred Reporting Items for Systematic Review and MetaAnalysis 10) methodology guidance was employed. Full texts were reviewed for relevant articles or where a decision re garding inclusion could not be made from the title and abstract. The reference list of relevant articles was also examined for any additional articles not identified from the database search. Stud ies were included if they compared the use of PRP versus any other treatment for PT. Single case reports, reviews, and non comparable studies were excluded. The methodology of the stud ies was carefully examined to ensure that they were true RCTs only. Data were extracted in a standardised manner. The com mon reported outcome for comparison was the Victorian Insti tute of Sports AssessmentPatella (VISAP) score 11) , which is the only validated scoring system developed specifically for patella tendinopathy. It assesses the severity of symptoms, patient's func tion, and ability to participate in sporting activities, giving a score from 0 (asymptomatic) to 100. The VISAP takes into account patient's pain during activities such as squatting, lunging, sitting and the duration of time during training before the pain becomes activity limiting. A metaanalysis of mean differences in VISAP score was per formed with use of a randomeffects model. Summary mean differences, standard errors (SEs), and 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using tau 
Results
From 556 published abstracts identified, 550 were excluded for nonpertinence including all nonRCTs. Six studies underwent a full abstract review, 3 of which were rejected due to not meeting inclusion criteria or duplication. Three full texts were reviewed; 1 was found to be a duplicate, which left 2 RCTs that met the inclu sion criteria and hence were included in the metaanalysis (Fig. 1) .
The first RCT by Dragoo et al. 12) in our metaanalysis com pared leukocyterich PRP injections with ultrasound guided dry needling of the patella tendon in the treatment of PT. Patients in both the test and control groups were instructed to follow a pro gram of eccentric exercises and had twice weekly physiotherapy sessions following the treatment. The second included RCT by Vetrano et al. 13) compared leuko cyterich PRP injections with focused extracorporeal shock wave therapy (ESWT). Both the PRP and ESWT groups were given a standardised stretching and muscle strengthening protocol to fol low for 2 weeks. Table 1 displays demographics and definitions of the two in cluded studies. Both RCTs used the VISAP questionnaire scores for reporting outcomes and this was the outcome utilised in the metaanalysis.
Metaanalysis of the two studies showed no significant differ Literature search undertaken using terms "patella", "patellar", and "platelet" in Pubmed, EMBASE, CINAHL,
CENTRAL databases Cochrane
Final inclusion for analysis (n=2) (Fig. 3) .
Discussion
The most important finding in our metaanalysis is that PRP injections are statistically better than the control group (ESWT and dry needling) at longer term (6 months or more) followup suggesting that PRP is an effective and worthwhile treatment for PT. PT is believed to be caused by degeneration of collagen fibres in the tendon, leading to microtearing, rather than due to an acute inflammatory process, which may be associated with failed healing due to poor vascularity within the tendon 14) . Current treatments for PT include nonsurgical options, such as eccentric exercises, ESWT, dry needling of the tendon, and PRP injections. These approaches are well established and they all aim to increase neovascularisation and promote cell growth and collagen synthe sis. Chen et al. 15) showed that ESWT promoted healing of Achil les tendonitis in rats by inducing transforming growth factorβ1 (TGFβ1) and insulinlike growth factor 1 (IGF1) production. These factors are known to play important roles in mediating cell proliferation and tissue regeneration of tendons. Cell proliferation and collagen synthesis were also found to be increased in tendons following ESWT in a number of papers 16, 17) . Further studies have shown that ESWT can cause neovascularisation at the bone tendon junction due to release of certain angiogenic mediators, such as vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase, and proliferating cell nuclear antigen 18, 19) . Indeed a number of studies have found ESWT to be beneficial to patients with PT over physiotherapy alone 20, 21) . Dry needling of affected tendons is thought to work in a similar way by causing bleeding and inflammation with local release of beneficial growth factors 22, 23) . An RCT in 2006 by Bahr et al. 24) showed no benefit of surgical tenotomy over eccentric exercises alone for the treatment of PT. Further studies by Peers et al. 25) showed comparable results be tween ESWT and surgical intervention in a crosssectional out come analysis for chronic patella tendinosis. Many centres now reserve surgical tenotomy as the last treatment option for PT due to inconsistent results and potential morbidity associated with surgery 24, 26) . PRP injections are also not a new concept and have been used since the 1970s. There are various PRP kits available; however, the common process involves taking a venous sample of blood from the patient using a venepuncture device and a bottle con taining an anticoagulant to prevent platelet activation prior to its use. This sample is placed into a centrifuge which is spun resulting in separation of the whole blood contents into three lay ers: the top platelet rich layer containing some white blood cells (WBC), the intermediate "buffy" layer containing mostly WBCs, and the third layer rich in red blood cells. The top plateletrich layer can be removed and used as leukocyterich PRP injections. A further centrifugation of the top layer and "buffy" layer can be done to produce a pure PRP injection 27) . Both studies in our metaanalysis used a leukocyterich PRP injection.
Platelets have the potential to release growth factors, such as TGFβ, VEGF, plateletderived growth factor, IGF1, and fibro blast growth factor, as well as cytokines which mediate healing within tendons 7, 28, 29) . There have been several noncontrolled studies reporting good outcomes with PRP use in PT. In a 31 patient study, Filardo et al. 7) found a statistically significant im provement in sport activity levels at the end of a course of PRP injections in patients with chronic refractory PT compared to those treated with physiotherapy alone. In a prospective study by Kon et al. 6) , 20 male athletes with refractory PT underwent PRP injections and all had a statistical improvement in questionnaire scores at 6month followup.
However, as our study demonstrates there is a paucity in RCTs evaluating the role of PRP injections in PT. We were able to iden tify only 2 such studies and these differed in the PRP regime they administered and in the control group they utilised. Vetrano et al. 13) found that both PRP injections and ESWT improved the VISAP score at 2, 6, and >12 months (p<0.005 for all). There was no significant difference in the scores at baseline and 2 months; however, there was significant difference between the groups at 6 months (PRP injection group, 86.7±14.2 vs. ESWT group, 73.7±19.9; p=0.014) and 12 months of followup (91.3±9.9 vs. 77.6±19.9; p=0.026). Dragoo et al. 12) found the VISAP scores of the PRP group had improved significantly more than the dry needling group at 12 weeks (p=0.02); however, the difference be tween the two groups was not significant at >26 weeks (p=0.66). The visual analog scale (VAS) score for pain was also used as an outcome measure in both included studies; however, this is not a specific questionnaire for PT. Vetrano et al. 13) showed that, similarly to the VISAP score, there was improvement in the VAS scores for 2 months, albeit not significant (p=3.58), but there was significant difference between the VAS scores at 6 months (PRP injection group, 2.4±1.9 vs. ESWT group, 3.9±2.3; p=0.028) and 12 months (1.5±1.7 vs 3.2±2.4; p=0.009). In the Dragoo et al. 12) study, the VAS pain score improved for both the dry needling and PRP groups at 12 and >26 weeks; however, there was no sig nificant difference between the two groups at either followup (12 weeks, p=0.13; >26 weeks, p=0.96). It is of interest that Dragoo et al. 12) found significant early (12 week) improvements in scores between the PRP and dry needling groups, but no significant differences at the late term followup (>26 weeks). In contrast, Vetrano et al. 13) found no significant difference between PRP and ESWT at early (2 month) follow up, but the PRP group scored significantly better on VISAP and VAS at 6 and 12 months. One possible explanation for these contrasting findings could be the number of PRP injections given: the Dragoo et al. 12) PRP group received one PRP injection, whereas in the study by Vetrano et al. 13) , the PRP group received two injections two weeks apart. It is possible that two PRP injec tions lead to an increased and prolonged inflammatory response, which takes a longer time to settle and allow clinical improve ment. When the results of the 2 studies were combined through a metaanalysis, there was no significant difference in mean VISA P scores between PRP injection and control at early assessment (2 or 3 months) but PRP was statistically better than control with regards to VISAP scores at longer followup (at 6 months or more than 6 months), suggesting that PRP is a viable alternative to other nonsurgical options.
The main limitation of this metaanalysis is that there are only 2 trials included, both of which were small in size and showed substantial heterogeneity with regards to the regime of PRP injec tions and type of control group used. The followup in our study was limited to 6 months or "6 months or more", and it would be beneficial to be able to compare outcomes further down the line with a followup at 12 months, etc. Nevertheless, metaanalyses are useful even in the presence of a small number of studies in that they allow pooling of data and potentially an early identifi cation of a beneficial or otherwise effect, whilst larger trials are awaited.
It is also possible that the difference at 6 months between PRP and control maybe due to some other factors other than the PRP injection itself. However, we feel this is less likely to be the cause of the observed difference, as patients were randomly assigned to the treatment and control groups, which would help deal with any unknown confounders. In addition, both groups received similar treatments other than the PRP injection-i.e. the same course of physiotherapy/exercise regime to follow.
Hence, within the limitations of this study, our results suggest that PRP does seem to be superior for refractory PT over other established nonsurgical treatments (such as dryneedling and ESWT) at 6 months post treatment. Larger RCTs comparing PRP versus other established treatments in PT are needed. In the
